These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 4087036)

  • 21. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW; Li D; McQuone SJ; Ralston R
    Laryngoscope; 2005 Mar; 115(3):391-404. PubMed ID: 15744147
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Poludan therapy of eye viral diseases].
    Krasnov MM; Kasparov AA; Vorob'eva OK; Ul'ianova TI; Gorbovitskaia GE; Malozhen SA; Kasparova EA; Fadeeva LL; Khaletskaia 'EV ; Koval'chuk KV; Pavliuk AS
    Vestn Oftalmol; 1997; 113(5):35-9. PubMed ID: 9508748
    [No Abstract]   [Full Text] [Related]  

  • 23. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
    Hoffman RM
    Methods Mol Med; 2005; 111():297-322. PubMed ID: 15911987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon: fantasies and facts.
    Dianzani F; Dolei A
    Dev Biol Stand; 1985; 60():3-13. PubMed ID: 2412916
    [No Abstract]   [Full Text] [Related]  

  • 25. [Experimental research to clinical application of interferons].
    Imamishi J; Tanaka A
    Gan To Kagaku Ryoho; 1984 Jan; 11(1):53-9. PubMed ID: 6198966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The medical significance of interferons and their inducers].
    Ershov FI
    Vestn Ross Akad Med Nauk; 2004; (2):9-13. PubMed ID: 15101201
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biological response modifiers.
    Oldham RK
    J Natl Cancer Inst; 1983 May; 70(5):789-96. PubMed ID: 6188871
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical discovery of ixabepilone, a highly active antineoplastic agent.
    Lee FY; Borzilleri R; Fairchild CR; Kamath A; Smykla R; Kramer R; Vite G
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):157-66. PubMed ID: 18347795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of DT-diaphorase in cancer chemoprevention and chemotherapy.
    Begleiter A; Leith MK; Curphey TJ; Doherty GP
    Oncol Res; 1997; 9(6-7):371-82. PubMed ID: 9406243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effectiveness of immunomodulators in experimental virus infections].
    Barinskiĭ IF; Nesterchuk SL
    Vopr Virusol; 1989; 34(6):645-50. PubMed ID: 2483777
    [No Abstract]   [Full Text] [Related]  

  • 31. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferons in the treatment of advanced breast cancer.
    Repetto L; Venturino A; Simoni C; Rosso M; Melioli G; Rosso R
    J Biol Regul Homeost Agents; 1993; 7(4):109-14. PubMed ID: 7517612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [The antibacterial efficacy of preparations of interferon and its inducers].
    Spivak NIa; Grabchenko NI; Lazarenko LN; Tovt-Korshinskaia MI; Ganova LA; Timoshok NA; Krivokhatskaia LD; Mikhaĭlenko ON; Karpov AV; Mikhaĭlenko TI; Zotsenko VN
    Mikrobiol Z; 1999; 61(1):32-45. PubMed ID: 10330873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of metastatic carcinoma cell growth in livers by poly(I):poly(C)/cationic liposome complex (LIC).
    Hirabayashi K; Yano J; Takesue H; Fujiwara N; Irimura T
    Oncol Res; 1999; 11(11-12):497-504. PubMed ID: 10905561
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potentiated antitumor effects of interleukin 12 and interferon alpha against B16F10 melanoma in mice.
    Dabrowska A; Giermasz A; Gołab J; Jakóbisiak M
    Neoplasma; 2001; 48(5):358-61. PubMed ID: 11845979
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Secondary microbial metabolites with potentials for antineoplastic actions: antineoplastic antibiotics and immunopotentiators].
    Umezawa H
    Gan To Kagaku Ryoho; 1983 Apr; 10(4 Pt 2):1071-86. PubMed ID: 6191672
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development.
    Peterson JK; Houghton PJ
    Eur J Cancer; 2004 Apr; 40(6):837-44. PubMed ID: 15120039
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Clinical phase II trial of a new antineoplastic drug--glyciphosphoramide].
    Sun Y
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1984 Aug; 6(4):273-6. PubMed ID: 6241067
    [No Abstract]   [Full Text] [Related]  

  • 39. Immunomodulation in cancer therapeutics.
    Ehrke MJ
    Int Immunopharmacol; 2003 Aug; 3(8):1105-19. PubMed ID: 12860167
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice.
    Geiger T; Müller M; Monia BP; Fabbro D
    Clin Cancer Res; 1997 Jul; 3(7):1179-85. PubMed ID: 9815797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.